Targeting HIV with GEM-91 and anti-HIV-1 ribozymes

&

Gene expression modulator 91 [GEM-91; Hybridon] and anti-HIV ribozymes are emerging as potential agents for combatting HIV infection. The first US phase I study with GEM-91 in patients infected with HIV has now been completed. In addition, research with anti-HIV-1 ribozymes has taken a step forward with the development of a novel ribozyme delivery strategy. The progress with these agents was discussed at the IIR Ltd conference, entitled ‘Antisense Therapy: Efficacy and Delivery of Antisense & Ribozyme Oligonucleotides’ [ London, UK; February 1995 ].